PR-Rx Blog

If They Know It's AI, Then Your Campaign Failed

Healthcare communications have the highest standards. How we use AI must reflect that.

Jun 26 • Joshua Mansbach @ PR-Rx

2

The U.S. FDA’s New Leadership Must Drive Global Regulatory Reform

The incoming commissioner and CBER director can catalyze change in the regulatory review processes for rare disease therapies to improve the lives of…

Jun 22 • Joshua Mansbach @ PR-Rx

1

100 Million Impressions, Zero Business Impact

Media coverage matters to PR, but market share and revenue are what make a difference in the Boardroom.

Jun 10 • Joshua Mansbach @ PR-Rx

2

May 2026

Some Brands Try Extra Hard To Make You Cringe

In the right context, it works. But if you’re wrong, it’ll be a spectacular failure.

May 27 • Joshua Mansbach @ PR-Rx

3

2

Everything You Need To Know About Great Communications Is In This Poem

So why are we ignoring the most powerful lesson ever written?

May 4 • Joshua Mansbach @ PR-Rx

1

April 2026

Vinay Prasad’s FDA exit is good for rare disease patients, but the new CBER head must repair eroded trust

FDA is signaling change, but success depends on more than a new leader at the Center for Biologics Evaluation and Research; it requires accountability…

Apr 27 • Joshua Mansbach @ PR-Rx

1

2

Kaizen: Because "Good Enough" Is the Enemy of Great Public Relations

PR pros can benefit from a Japanese philosophy that will transform results and improve ROI

Apr 6 • Joshua Mansbach @ PR-Rx

4

2

March 2026

Outside My Comfort Zone: A Public Relations Pro’s Foray Into Journalism

I walked in the shoes of a reporter, and it made me better at PR

Mar 23 • Joshua Mansbach @ PR-Rx

4

4

Rare Disease Patients Can’t Wait for Regulatory Process

The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the…

Mar 12 • Joshua Mansbach @ PR-Rx

3

February 2026

Balancing Safety Access in Rare Disease: Lessons From Sarepta

Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example…

Feb 27 • Joshua Mansbach @ PR-Rx

1

Op-Eds: The not-so-secret weapon that PR pros should wield more often

This “old school” tactic is new again, and now is the time to master writing them

Feb 23 • Joshua Mansbach @ PR-Rx

2

1

For PR To Evolve, Press Releases Must Become Extinct

One-way dialogue doesn’t win customers. Retire the release, and start a conversation.

Feb 9 • Joshua Mansbach @ PR-Rx

4

4

1